Forum Atlas
PricingMethodologyDevelopersAbout
Log inStart free
Health

ForumHealth

Pharma + payer + provider + medtech + health-IT — one synthesis layer.

Five sub-modules covering the value chain end to end: pharma/biotech (development → approval → launch), payer (CMS + commercial), provider (systems + IDNs), medtech, health-IT.

Start free on ForumHealth See a sample brief

Source landscape

1,050+

catalogued health sources — regulatory, financial, trade press, academic, patents, court records, vendor blogs, conference catalogs

PhasePhase 1 — active build
Sub-modules5
Personas tuned6
Wave-2 target300+ sources

Featured entities

PfizerUnitedHealthHCA HealthcareModernaEpic Systems

Personas

Six tuned briefs for the health buyer set.

Each persona gets section structure, source weights, and citation depth tuned to its job-to-be-done. Briefs are 400–800 words and arrive at 06:00 customer local.

P1

Pharma-biotech equity analyst

P2

Healthcare VC + growth

P3

Payer + provider strategy + M&A

P4

Health regulatory counsel (FDA + CMS + DOJ + FTC + state)

P5

Health journalist + analyst

P6

Health-tech founder + commercial operator

Forum Brief — Health

Continuous per-persona synthesis across 5 sub-modules. Citation-validated. Voice-readable.

Forum Forecast — Health

Monte-Carlo probability distributions on M&A, regulatory, capacity, and exec movement events. 3 forecast types per persona at v1.

Forum Network — Health

Cross-sector entity graph linking Health entities to their appearances in adjacent sectors. Featuring Pfizer and UnitedHealth.

Brief preview

Two sections from a sample Health brief.

Headlines

Wiz disclosed a $32B all-stock acquisition by Alphabet, clearing antitrust review faster than the Mandiant deal 12. Palo Alto Networks raised FY26 product revenue guidance by 300bps on platform-consolidation momentum 3. CrowdStrike's earnings call previewed an ITDR module landing in Q3, narrowing the gap to Microsoft Defender's identity surface 45.

Competitor moves

Microsoft positioned its E5+Defender bundle as the default SOC for mid-market customers in a 2026-05-19 Build keynote 6, with Sentinel-as-XDR pricing moving from per-event to per-asset 7. The shift compresses the per-seat economics of pure-play SIEM vendors and directly pressures Splunk's renewal cycle 8.

Zscaler announced a private CrowdStrike-aligned XDR integration in a 2026-05-21 press release 9, telegraphed at RSA 2026 panel discussion 10. Cloudflare's API-security pricing pivoted to consumption-based on 2026-05-23, ending the flat-rate model and aligning with Wiz pricing posture 11.

Competitive teardown

What we add vs. the incumbents.

Each incumbent covers part of the health landscape at a premium price point. Forum Atlas aggregates them — and adds capabilities the human-analyst cost structure cannot fund.

IQVIA

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Evaluate Pharma

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Komodo Health

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Trilliant Health

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Fierce Pharma

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Cross-sector moat

Health entities that touch other sectors.

Forum Network resolves each Health entity across every sector it touches — letting you see, for example, how an M&A move in Tech reshapes Cyber exposure or Defense supplier dynamics.

Microsoft

MSFT
TechCyberSpaceDefenseHealthEnergyFinance

appears in 7 sectors · importance 99.6

Alphabet

GOOGL
TechCyberHealthAutoComms

appears in 5 sectors · importance 98.7

Apple

AAPL
TechCommsHealthAuto

appears in 4 sectors · importance 98.4

Amazon

AMZN
TechInfraHealthCommsEnergy

appears in 5 sectors · importance 98.2

Anthropic

TechCyberHealthFinance

appears in 4 sectors · importance 96.1

NVIDIA

NVDA
TechAutoHealthDefense

appears in 4 sectors · importance 99.1

ForumHealth

Try Forum Atlas on Health.

The free tier includes the top-3 items from each brief in Health. No credit card.

Start free See pricing
Forum Atlas

Industry intelligence you can trace to the source. Continuous synthesis across 12 commercial sectors, citation-validated by default.

Delaware C-corp · US-based, US-hosted

Forum Atlas, Inc.

Product

How it worksPricingSample BriefSample ForecastNetwork previewChangelog

Company

AboutManifestoCareersPressBlogSupport

Developers

API QuickstartAPI ReferenceSDKsWebhooksBounty Program

Sectors

ForumDefenseForumCyberForumSpaceForumMaterialsForumTechForumHealthForumEnergyForumFinanceForumCommsForumInfraForumAutoForumAg

Legal

PrivacyTermsDPAAcceptable useSubprocessorsMethodologyAccuracyTransparencyShadow ledgerCitation disciplineSecurity

© 2026 Forum Atlas, Inc. All rights reserved.

Brief preview

A recent Health brief — first two sections.

View full brief

Headlines

Regulatory approvals dominated the pharma/medtech news cycle. The FDA approved Revolution Medicines' pancreatic cancer treatment, the first therapy to target a genetic driver of the disease; the pivotal trial showed a median overall survival of 13.2 months as a second-line therapy versus 6.7 months for standard chemotherapy 1. Separately, the FDA granted accelerated approval to Replimune's melanoma treatment RP1, now marketed as Tudriqev, following a contested review in which agency staff flagged trial-design concerns but advisers backed efficacy signals given unmet patient need; Replimune disclosed a list price of $450,000 per course of therapy before rebates and discounts 2. In medtech, Implantica AG announced it received FDA Premarket Approval (PMA) for RefluxStop, opening the U.S. market to the device 3. Together, the approvals span oncology biologics, gene-targeted therapeutics, and device-based interventions, underscoring continued FDA activity across therapeutic modalities even as pricing scrutiny — evident in Tudriqev's list price disclosure — remains a parallel storyline for payers and investors tracking net realized pricing versus headline figures.

A real, AI-generated Health brief from the live corpus — every claim citation-validated, the same discipline every Forum Atlas brief carries.